| Kimberly C Stone, MD | |
|
3701 S Clarkson St, Ste 300, Englewood, CO 80113-3960 | |
| (303) 806-8600 | |
| (303) 806-8629 |
| Full Name | Kimberly C Stone |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 30 Years |
| Location | 3701 S Clarkson St, Englewood, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093819369 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | CO38869 (Colorado) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kimberly C Stone Md Pc | 5294813614 | 2 |
News Archive
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
Democrats in the Virginia General Assembly plan to propose legislation that would authorize human embryonic stem cell research in the state, Jesse Furgeson, spokesperson for state House Democratic Caucus Chair Brian Moran, said recently, the Richmond Times-Dispatch reports.
Celsion Corporation announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
› Verified 4 days ago
| Entity Name | Kimberly C Stone Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053597849 PECOS PAC ID: 5294813614 Enrollment ID: O20080424000508 |
News Archive
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
Democrats in the Virginia General Assembly plan to propose legislation that would authorize human embryonic stem cell research in the state, Jesse Furgeson, spokesperson for state House Democratic Caucus Chair Brian Moran, said recently, the Richmond Times-Dispatch reports.
Celsion Corporation announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly C Stone, MD 3701 S Clarkson St Ste 320, Englewood, CO 80113-3960 Ph: (303) 740-4883 | Kimberly C Stone, MD 3701 S Clarkson St, Ste 300, Englewood, CO 80113-3960 Ph: (303) 806-8600 |
News Archive
Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that Firmenich SA, the world's largest privately-owned fragrance and flavor company, has made a decision to proceed with commercial development of S6973, Senomyx's enhancer of sucrose (table sugar) that has demonstrated the ability to reduce up to 50% of the sugar in a variety of products while maintaining the taste of natural sugar.
Democrats in the Virginia General Assembly plan to propose legislation that would authorize human embryonic stem cell research in the state, Jesse Furgeson, spokesperson for state House Democratic Caucus Chair Brian Moran, said recently, the Richmond Times-Dispatch reports.
Celsion Corporation announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial.
AstraZeneca today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic breast cancer who have not previously been treated with any hormonal therapy. The Phase III study is designed to evaluate the efficacy and tolerability of fulvestrant 500 mg compared to anastrozole 1 mg in this patient population.
› Verified 4 days ago
James V Twede, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3701 S Clarkson St Ste 400, Englewood, CO 80113 Phone: 303-761-7797 Fax: 303-789-2995 | |
Kaitlyn Laurel Pell, PA-C Dermatology Medicare: Not Enrolled in Medicare Practice Location: 125 Inverness Dr E Ste 340, Englewood, CO 80112 Phone: 303-747-6719 Fax: 303-951-0578 | |
Ms. Amy J Huber, PAC Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9570 S Kingston Ct, Suite 100, Englewood, CO 80112 Phone: 303-350-4500 Fax: 303-350-4501 | |
Tanya Nicole Riddle, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3701 S Clarkson St Ste 400, Englewood, CO 80113 Phone: 303-761-7797 Fax: 303-789-2995 | |
Dr. Richard G Asarch, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3701 S Clarkson St Ste 400, Englewood, CO 80113 Phone: 303-761-7797 Fax: 303-789-2995 | |
Dr. Annelise Lorelei Dawson, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 499 E Hampden Ave Ste 390, Englewood, CO 80113 Phone: 303-390-0795 |